Company
ILC Therapeutics
A cytokine-engineering company pioneering Hybrid Interferons as first-in-class therapeutics
- Status
- Operatingas of 2026-09-22
- Business model
- B2B
- Headquarters
- United Kingdom
- Customers
- seeking co-development partners of novel candidates in defined indications and licencing partners for assets at clinical stage
- Legal name
- ILC THERAPEUTICS LTD
- ilctherapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 22 September 2026
About
ILC Therapeutics (ILCT) is a specialist, UK-based cytokine engineering company designing hybrid interferons, a novel drug class with improved therapeutic profiles, with an initial focus on infectious disease.
Funding snapshot
- Latest round
- Undisclosed2024-09-11
Funding rounds
- Round, 2024
- 2024-09-11
- Round, 2021
- 2021-09-06
- Round, 2020
- 2020-12-01
Products
- Other
- Alfacyte
- Other
- Caniferon
Loading relationship preview